Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells

Blood

Volumn 96, Issue 12, 2000, Pages 3900-3906

  Wen, Jinghai ^a   Ramadevi, Nimmanapalli ^a   Nguyen, Diep ^a   Perkins, Charles ^a   Worthington, Elizabeth ^a   Bhalla, Kapil ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; APO 2L; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYTARABINE; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MONOCYTE; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

EID: 0034551746     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3900     Document Type: Article

References (53)

1. Death receptors: Signaling and modulation
2. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
3. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
4. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
5. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
6. Caspases: Intracellular signaling by proteolysis
7. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
8. Caspase activation: The induced-proximity model
9. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
10. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
11. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-X(L) prevents this release but not tumor necrosis factor-R1/Fas death
12. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
13. An Apaf-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
14. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis
15. Apoptotic pathways: The roads to ruin
16. The role of Apaf-1, caspase-9, and bid proteins in etoposideor paclitaxel-induced mitochondrial events during apoptosis
17. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
18. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
19. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/INFR1-induced apoptosis
20. IAPs block apoptotic events induced by caspase-B and cytochrome c by direct inhibition of distinct caspases
21. X-linked IAP is a direct inhibitor of cell-death proteases
22. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
23. The treatment of adult acute myeloid leukemia
24. Pharmacology and molecular mechanism of action or resistance of antineoplastic agents: Current status and future potential
25. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
26. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
27. Molecular determinants of response to TRAIL in killing of normal and cancer cells
28. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
29. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-X(L)
30. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
31. Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis
32. Estrogen increases intracellular p26Bcl-2 or p21 Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
33. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
34. 1-β-Darabinofuranosylcytosine-, mitoxantrone- and paclitaxel-induced apoptosis in HL-60 cells: Improved method for detection of internucleosomal DNA fragmentation
35. Overexpression of Bcl-2 or Bcl-X(L) inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human AML HL-60 cells
36. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
37. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases
38. Control of apoptosis and mitotic spindle checkpoint by survivin
39. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
40. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling
41. Inhibition of Fas death signals by FLIPs
42. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
43. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis
44. Inhibition of death receptor signals by cellular FLIP
45. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
46. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis
47. Two CD95 (Apo-1/Fas) signaling pathways
48. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
49. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1
50. Thymineless death in colon carcinoma cells is mediated via fas signaling
51. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
52. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
53. p-53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha